• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 30, 2016

View Archived Issues

Saniona, Boehringer Ingelheim enter $101M ion channel discovery pact in schizophrenia

DUBLIN – Shares in Saniona AB gained 25 percent Monday on news of an ion channel drug discovery pact in schizophrenia with Boehringer Ingelheim GmbH worth up to €90 million (US$101 million) in up-front and milestone payments. Read More

European Society of Cardiology Congress

Amgen Inc., of Thousand Oaks, Calif., said that new analyses of data show Repatha (evolocumab) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients across cardiovascular risk subgroups or with familial hypercholesterolemia. Read More

Other news to note

Tetragenetics Inc., of Arlington, Mass., said it formed a new partnership with one of the world's top 10 pharma companies. Read More

In the clinic

NLS Pharma Group, of Stans, Switzerland, started enrollment for a phase II experiment to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release formulation of mazindol in adults with DSM-5 attention deficit hyperactivity disorder (ADHD). Read More

Eli Lilly to FDA: Follow the science in defining a protein

With a potential generic already in the wings, Eli Lilly and Co. is hoping to bring the curtain down permanently on ANDAs referencing its blockbuster osteoporosis drug Forteo. Read More

CTI Biopharma clears path to key pacritinib meeting with FDA

Top-line data from CTI Biopharma Corp.'s phase III trial of pacritinib, a JAK2/FLT3 multikinase inhibitor for high-risk patients with advanced myelofibrosis showed the treatment demonstrated statistically significant improvement in spleen volume reduction vs. best available treatment. Read More

Mylan to roll out generic rather than drop Epipen price

Mylan NV's announcement Monday that it will launch a generic of its Epipen did little to quell the public shaming as skeptics speculated about the motives behind the move. Read More

Macrocure reverse merger offers running 'Leap' into public markets

Five-year-old Leap Therapeutics Inc. stands to become a public company as the surviving entity in its merger with the Israeli biopharma, Macrocure Ltd., which will operate as a wholly owned subsidiary. Leap, of Cambridge, Mass., was founded in 2011 and raised $30.5 million the same year in a round led by Healthcare Ventures and its funds, according to SEC filings. Earlier this year, Healthcare Ventures was said to have combined its portfolio companies Healthcare Pharmaceuticals Inc. and GITR Inc. into Leap. Read More

Beige fat cells stay the course through autophagy inhibition

Energy-burning brown fat cells have generated much heat as a possible weapon in the fight against obesity. Read More

Takeda to restructure R&D ops with focus on Japan, Boston

TOKYO – Takeda Pharmaceutical Co. Ltd., of Japan, plans to restructure its research and development operations to focus primarily on the areas of oncology, gastroenterology and central nervous system, as well as vaccines. Read More

Crownbio spin-off to develop China-discovered oncology assets in U.S.

SHANGHAI – Newly created oncology biotech, CBT Pharmaceuticals, of Santa Clara, Calif., has received $9.75 million in series A financing from venture investors led by Orbimed Healthcare Fund Management Asia, with an additional $2 million available in warrants. Read More

Financings

Cel-Sci Corp., of Vienna, Va., said it closed its registered direct offering with institutional investors for gross proceeds of $5 million. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe